Chlorzoxazone


Concise Prescribing Info
Indications/Uses
Painful muscle spasm associated w/ musculoskeletal conditions.
Dosage/Direction for Use
Adult: PO Initial: 500 mg 3-4 times/day, may reduce to 250 mg 3-4 times/day. Max: 750 mg 3-4 times/day.
Administration
Should be taken with food.
Contraindications
Hepatic impairment.
Special Precautions
Patient w/ history of liver disease, porphyria. Pregnancy. Patient Counselling This drug may cause CNS depression, if affected, do not drive or operate machinery. This drug may cause orange or reddish-purple urine colouration. Monitoring Parameters Monitor LFT periodically; assess signs or symptoms of hepatotoxicity.
Adverse Reactions
Significant: Elevated liver enzymes (i.e. ALT, AST, bilirubin, alkaline phosphatase). Nervous: Drowsiness, dizziness, headache, light-headedness, malaise, overstimulation. GI: Anorexia, nausea, vomiting, heartburn, abdominal distress, constipation, diarrhoea. Hepatic Jaundice. Genitourinary: Urine discolouration. Dermatologic: Rashes, petechiae, ecchymosis, urticaria, pruritus.
Potentially Fatal: Rarely, hepatocellular toxicity.
Drug Interactions
Enhanced CNS effect w/ other CNS depressants. Increased serum concentration w/ disulfiram, isoniazid.
CIMS Class
ATC Classification
M03BB03 - chlorzoxazone ; Belongs to the class of oxazol, thiazine, and triazine derivative agents. Used as centrally-acting muscle relaxants.
Disclaimer: This information is independently developed by CIMS based on chlorzoxazone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in